Search
sotatercept-csrk (Winrevair)
Indications:
- reduces pulmonary vascular resistance in patients receiving therapy for pulmonary arterial hypertension (FDA-approved)
Dosage:
- 0.3-0.7 mg/kg of body weight every 3 weeks SQ
Injection: 45 mg, 60 mg
Adverse effects:
- thrombocytopenia
- erythrocytosis
- cardiac arrest (1 death in 24 week trial of 106 patients) [1]
Mechanism of action:
- binds activins & growth differentiation factors
- attempts to restore balance between growth-promoting & growth-inhibiting signaling pathways
- sotatercept decreases N-terminal pro-B-type natriuretic peptide levels
General
pulmonary agent
recombinant protein; chimer
References
- Humbert M, McLaughlin V, Gibbs JSR et al
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
N Engl J Med 2021; 384:1204-1215. April 1.
PMID: 33789009
https://www.nejm.org/doi/full/10.1056/NEJMoa2024277
- Lou N
Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension.
Biologic should arrive on pharmacy shelves before May.
MedPage Today March 27, 2024
https://www.medpagetoday.com/cardiology/hypertension/109372
- HIGHLIGHTS OF PRESCRIBING INFORMATION
Winrevair sotatercept-csrk for injection, for subcutaneous use
https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf